Abbott, Dharmacon to develop new siRNA-based therapeutics

By Elaine Rigoli

Tampa, Fla., July 6 - Abbott and Dharmacon, Inc. announced a collaboration to develop new therapeutic agents based on a gene-silencing technology of RNA interference.

The companies said the research could extend drug-discovery efforts into disease targets where traditional discovery technologies have not been successful.

During the collaboration, Abbott and Dharmacon will work to identify therapeutic siRNAs for multiple therapeutic areas, initially focusing on oncology.

Abbott will manage the drug-discovery and development process and will be responsible for commercialization of products that result from the collaboration.

Financial terms are not being disclosed.

Abbott is a global health care company with headquarters in Abbott Park, Ill.

Dharmacon is a business unit within the Fisher Biosciences group located in Lafayette, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.